Last C$0.84 CAD
Change Today 0.00 / 0.00%
Volume 6.5K
DMA On Other Exchanges
Symbol
Exchange
Berlin
Venture
OTC US
As of 2:14 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Open
C$0.84
Previous Close
C$0.84
Day High
C$0.84
Day Low
C$0.84
52 Week High
09/5/13 - C$1.49
52 Week Low
04/23/13 - C$0.75
Market Cap
49.5M
Average Volume 10 Days
21.6K
EPS TTM
C$-0.17
Shares Outstanding
58.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound, DM199, is a recombinant human protein known as rhKLK1, which is under evaluation in Phase I/II clinical trial for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing a monoclonal antibody, DM204, which is in preclinical development for the treatment of Type 2 diabetes. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$288.4K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: C$226.6K
Vice President of Finance
Total Annual Compensation: C$74.5K
Consulting Chief Medical Officer
Total Annual Compensation: C$11.8K
Vice-President of Research
Total Annual Compensation: C$182.3K
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

DiaMedica Appoints John Savage as CFO

DiaMedica has appointed John Savage as the company's CFO. Mr. Savage has more than 17 years of experience working with publicly traded companies. Prior to joining DiaMedica, Mr. Savage was Director of Corporate Accounting at UnitedHealth Group.

Diamedica Inc. Appoints John Savage as Chief Financial Officer

Diamedica Inc. announced the appointment of Mr. John Savage as the company's Chief Financial Officer. Mr. Savage has more than 17 years of experience working with publicly traded companies. Prior to joining DiaMedica, Mr. Savage was Director of Corporate Accounting at UnitedHealth Group.

DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients

DiaMedica announced it has met the primary endpoints of safety and tolerability from the recently completed 16-day Phase 1 multiple ascending dose (MAD) of DM199 in healthy volunteers. DiaMedica has also initiated dosing of the first Type 2 diabetic patients in a one-month DM199 Phase 2 clinical trial. DM199 is a recombinant human tissue kallikrein-1 (rhKLK-1) protein and a novel treatment for diabetes and its complications by targeting the Kallikrein-Kinin System. In the recently completed Phase 1 MAD clinical trial of 18 healthy volunteers, DM199 was well-tolerated at all three dose levels and met the primary endpoints of safety and tolerability. DM199 also demonstrated a favorable pharmacokinetic profile supporting the potential for weekly dosing. Based on the Phase 1 clinical results, DiaMedica has initiated a Phase 2 clinical study in patients with Type 2 diabetes to evaluate the safety, tolerability and pharmacokinetics of two dose levels of DM199 and its effects on diabetes biomarkers including: HOMA2-IR, fasting glucose and plasma insulin, meal tolerance test, lipids, HbA1c and other metabolic markers. The one-month, randomized, double-blinded, placebo-controlled study is expected to enroll 36 patients with Type 2 diabetes. The patients will start with a one-month wash out of their diabetes mediations and then be sequestered for the one-month study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.84 CAD 0.00

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies
 

Industry Analysis

DMA

Industry Average

Valuation DMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 81.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit www.diamedica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.